Loading, please wait...
Microsoft Teams meeting
Meeting ID: 227 113 554 364 761
Passcode: i3ga6Yd7
Phone conference ID: 170 494 912#
Date: Jun 11, 2026 03:15 PM - 04:15 PM
Fee
$0.00
CE Hours
2.00
CE Units
0.200
Registration closes on Jun 18, 2026 12:00 AM
Activity Type
- Application
Target Audience(s)
- Pharmacists
- Pharmacy Technicians
Accreditation(s)
|
WellStar Health System is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
Participants who attend the entire activity, complete and pass the post-test (>70%), and complete the activity evaluation will receive CE credit. Credit will be uploaded electronically and available in CPE Monitor after completion of required elements.
Thu, Jun 11, 2026
Thu, Jun 11, 2026
Microsoft Teams meeting
Meeting ID: 271 997 504 757 465
Passcode: BD9vx6Jj
Dial in by phone
+1 470-344-8779,,942715451# United States, Atlanta
Phone conference ID: 942 715 451#
For organizers: Meeting options | Reset dial-in PIN
Objectives
- Describe the pathophysiology and staging of Type 1 diabetes, including the role of autoimmune ?-cell destruction.
- Recognize the mechanism of action and clinical effects of teplizumab in delaying disease progression.
- Identify patients at risk for progression to Stage 3 Type 1 diabetes and appropriate candidates for teplizumab therapy.
- Apply evidence-based strategies for the use, monitoring, and management of teplizumab in clinical practice.
Speaker(s)/Author(s)
|
Mariam Diaby, PharmD
|
Activity Number
0483-0000-26-008-L01-P
Date:
06/11/26
Time:
03:15 PM - 04:15 PM
CE Hours
1.00
Location
Wellstar Cobb Auditorium and MS Teams
Microsoft Teams meeting
Meeting ID: 227 113 554 364 761
Passcode: i3ga6Yd7
Phone conference ID: 170 494 912#
Objectives
- Describe the purpose and basic mechanism of teplizumab in delaying Type 1 diabetes
- Recognize common adverse effects and the importance of monitoring during therapy
- Explain the basic administration process and infusion considerations for teplizumab
Speaker(s)/Author(s)
|
Mariam Diaby, PharmD
|
Activity Number
0483-0000-26-008-L01-T
Date:
06/11/26
Time:
03:15 PM - 04:15 PM
CE Hours
1.00
Location
Wellstar Cobb Auditorium and MS Teams